Arvinas Inc.

61.34+0.8900+1.47%Vol 358.38K1Y Perf 36.91%
Apr 13th, 2021 16:00 DELAYED
BID59.01 ASK77.18
Open60.45 Previous Close60.45
Pre-Market- After-Market-
 - -  - -%
Target Price
99.63 
Analyst Rating
Strong Buy 1.22
Potential %
62.42 
Finscreener Ranking
★★★★★     60.14
Insiders Trans % 3/6/12 mo.
-100/-73/-58 
Value Ranking
★★★★+     59.80
Insiders Value % 3/6/12 mo.
-100/10/8 
Growth Ranking
★★★★+     68.65
Insiders Shares Cnt. % 3/6/12 mo.
-100/18/15 
Income Ranking
 —    -
Market Cap3.00B 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
57.00 
Earnings Date
27th Apr 2021

Today's Price Range

58.9862.08

52W Range

19.6892.77

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-4.69%
1 Month
-20.19%
3 Months
-30.06%
6 Months
143.32%
1 Year
36.91%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ARVN61.340.89001.47
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Financial StrengthValueIndustryS&P 500US Markets
14.20
14.30
0.00
0.01
-1 834.90
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
-
-403.50
-389.40
-306.90
-
RevenueValueIndustryS&P 500US Markets
15.56M
0.32
34.57
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.78-0.99-26.92
Q03 2020-0.67-0.79-17.91
Q02 2020-0.58-0.65-12.07
Q01 2020-0.59-0.565.08
Q04 2019-0.53-0.56-5.66
Q03 2019-0.310.21167.74
Q02 2019-0.46-0.55-19.57
Q01 2019-0.47-0.462.13
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.77-28.33Negative
6/2021 QR-0.81-20.90Negative
12/2021 FY-3.65-17.36Negative
12/2022 FY-3.91-7.71Negative
Next Report Date27th Apr 2021
Estimated EPS Next Report-0.77
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume358.38K
Shares Outstanding48.87M
Trades Count5.96K
Dollar Volume17.90M
Avg. Volume491.75K
Avg. Weekly Volume323.97K
Avg. Monthly Volume459.91K
Avg. Quarterly Volume464.62K

Arvinas Inc. (NASDAQ: ARVN) stock closed at 61.34 per share at the end of the most recent trading day (a 1.47% change compared to the prior day closing price) with a volume of 358.38K shares and market capitalization of 3.00B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 133 people. Arvinas Inc. CEO is John Houston.

The one-year performance of Arvinas Inc. stock is 36.91%, while year-to-date (YTD) performance is -27.78%. ARVN stock has a five-year performance of %. Its 52-week range is between 19.68 and 92.77, which gives ARVN stock a 52-week price range ratio of 57.00%

Arvinas Inc. currently has a PE ratio of -21.40, a price-to-book (PB) ratio of 4.90, a price-to-sale (PS) ratio of 189.85, a price to cashflow ratio of 25.60, a PEG ratio of 2.32, a ROA of -23.42%, a ROC of -59.20% and a ROE of -27.47%. The company’s profit margin is -%, its EBITDA margin is -389.40%, and its revenue ttm is $15.56 Million , which makes it $0.32 revenue per share.

Of the last four earnings reports from Arvinas Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.77 for the next earnings report. Arvinas Inc.’s next earnings report date is 27th Apr 2021.

The consensus rating of Wall Street analysts for Arvinas Inc. is Strong Buy (1.22), with a target price of $99.63, which is +62.42% compared to the current price. The earnings rating for Arvinas Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Arvinas Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Arvinas Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.88, ATR14 : 5.40, CCI20 : -87.72, Chaikin Money Flow : -0.14, MACD : -3.35, Money Flow Index : 40.78, ROC : -2.36, RSI : 41.01, STOCH (14,3) : 36.26, STOCH RSI : 0.44, UO : 45.19, Williams %R : -63.74), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Arvinas Inc. in the last 12-months were: Edward Kennedy (Buy at a value of $199 909), Ian Taylor (Option Excercise at a value of $103 296), John Houston (Option Excercise at a value of $728 960), John Houston (Sold 44 000 shares of value $3 466 601 ), Liam Ratcliffe (Buy at a value of $9 999 990), Liam Ratcliffe (Option Excercise at a value of $286 780), Ronald Peck (Option Excercise at a value of $531 600), Ronald Peck (Sold 21 256 shares of value $1 581 482 ), Sean A. Cassidy (Option Excercise at a value of $755 440), Sean A. Cassidy (Sold 51 959 shares of value $3 892 108 ), Timothy M. Shannon (Buy at a value of $193 800), Timothy M. Shannon (Option Excercise at a value of $570 163)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (88.89 %)
7 (77.78 %)
8 (88.89 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (11.11 %)
2 (22.22 %)
1 (11.11 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.22
Strong Buy
1.44
Strong Buy
1.22

Arvinas Inc.

Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases.

CEO: John Houston

Telephone: +1 203 535-1456

Address: 395 Winchester Avenue, New Haven 06511, CT, US

Number of employees: 133

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

55%45%

Bearish Bullish

45%55%

News

Stocktwits